Angiopoietin-2 early increase to predict benefit from regorafenib in metastatic colorectal cancer (mCRC) patients: The prospective REGOLAND study.

Federica Marmorino,Carlotta Antoniotti,Alessandra Boccaccino,Maria Antista,Nadia Zaffaroni,Gemma Zucchelli,Antonia Martinetti,Elisa Campi,Daniele Rossini,Elisa Sottotetti,Beatrice Borelli,Francesca Corti,Veronica Conca,Roberto Moretto,Marco Maria Germani,Alfredo Falcone,Mirella Giordano,Gianluca Masi,Filippo Pietrantonio,Chiara Cremolini

Angiopoietin-2 early increase to predict benefit from regorafenib in metastatic colorectal cancer (mCRC) patients: The prospective REGOLAND study.

2021

e15566Background: Regorafenib is a treatment option for refractory mCRC patients with no validated predictors of benefit. We previously showed that, among several circulating angiogenic factors, lo...

Keywords:

Refractory
treatment options
Internal medicine
Colorectal cancer
Regorafenib
Oncology
Medicine
Angiopoietin 2

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations